$NASDAQ:KNTE

Kinnate Biopharma’s KIN-2787 Inhibitor Receives Fast Track FDA Designation for Melanoma Treatment

Trending News 🌧️ Kinnate Biopharma Intrinsic Value – Kinnate Biopharma($NASDAQ:KNTE)’s clinical-stage oncology inhibitor, KIN-2787, has received Fast Track FDA designation [...]

By |September 22, 2022|Categories: Intrinsic Value|Tags: , , |0 Comments
Go to Top